PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Siehler, J. ; Blöchinger, A. ; Meier, M. ; Lickert, H.

Engineering islets from stem cells for advanced therapies of diabetes.

Nat. Rev. Drug Discov. 20, 920–940 (2021)
Verlagsversion Postprint DOI PMC
Open Access Green
Diabetes mellitus is a metabolic disorder that affects more than 460 million people worldwide. Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells, whereas type 2 diabetes (T2D) is caused by a hostile metabolic environment that leads to β-cell exhaustion and dysfunction. Currently, first-line medications treat the symptomatic insulin resistance and hyperglycaemia, but do not prevent the progressive decline of β-cell mass and function. Thus, advanced therapies need to be developed that either protect or regenerate endogenous β-cell mass early in disease progression or replace lost β-cells with stem cell-derived β-like cells or engineered islet-like clusters. In this Review, we discuss the state of the art of stem cell differentiation and islet engineering, reflect on current and future challenges in the area and highlight the potential for cell replacement therapies, disease modelling and drug development using these cells. These efforts in stem cell and regenerative medicine will lay the foundations for future biomedical breakthroughs and potentially curative treatments for diabetes.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
84.694
13.116
25
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Insulin-producing Cells; Pancreatic Beta-cells; Mesenchymal Stromal Cells; Development Success Rates; In-vitro; Progenitor Cells; Alpha-cell; Endocrine Pancreas; Edmonton Protocol; Secreting Cells
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1474-1776
Zeitschrift Nature Reviews - Drug Discovery
Quellenangaben Band: 20, Heft: , Seiten: 920–940 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Regeneration Research (IDR)
Helmholtz Pioneer Campus (HPC)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
Pioneer Campus
PSP-Element(e) G-502300-001
G-510002-001
Förderungen Technical University Munich
Helmholtz Association
German Center for Diabetes Research (DZD e.V.)
German Federal Ministry of Education and Research (BMBF)
European Union
DOI 10.1038/s41573-021-00262-w
WOS ID WOS:000683643300001
Scopus ID 85112200950
PubMed ID 34376833
Erfassungsdatum 2021-09-20
[➜Korrektur melden]